Clinical Trial Update: TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase II adjuvant therapy study in resectable non-small cell lung cancer using L-TIL plus tislelizumab for patients who d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• L-TIL
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: NSCLC | Phase 2 | Status: RECRUITING